Navigation Links
Grant for brain tumor and deafness research
Date:7/27/2009

Researchers at the Peninsula Medical School have received a grant of over 39,000 from the charity Deafness Research UK, to investigate the role of brain tumours causing deafness in children and adults and the development of therapies using in vitro models.

These tumours and a variety of other tumours are caused by mutations affecting a protein called merlin, which in turn cause cancers in a range of cell types including Schwann cells in the nervous system. Schwann cells produce the sheaths that surround and insulate neurons.

Although the tumours are benign, they are frequent. They can be inherited and come in numbers. The sheer number of them can overwhelm a patient, often leading to deafness and eventually to death. Patients can suffer from 20 to 30 tumours at any one time, and the condition typically affects older children and young adults.

No therapy, other than invasive surgery aiming at a single tumour and which may not eradicate the full extent of the tumours, exists. The hereditary condition affects one in every 2,500 people worldwide. It can affect any family, regardless of past history, through gene mutation and currently there is no cure.

In some cases, pressure from the tumours affect the process of hearing leading to hearing loss or total deafness. The research will use a human acoustic neuroma in vitro model to identify how and why the tumours grow and eventually lead to hearing damage, and to test drug-based therapies designed to alleviate the problem.

The research is led by Professor Oliver Hanemann, Chair of Clinical Neurobiology at the Peninsula Medical School. He said: "We have already achieved some success in re-profiling an existing drug called sorafenib by using the human in-cell model. The re-profiled drug has a positive affect on multiple brain tumours. As a consequence, we can go straight to clinical trials and introduce therapies to patients sooner rather than later using sorafenib or similar drugs.."

Vivienne Michael, Chief Executive of Deafness Research UK, said: "This is clearly an important research project that could significantly improve the treatment available for those with acoustic neuroma and the charity is delighted to be funding it. Acoustic neuroma is worrying enough in its own right; when multiple tumours occur they need treating and traditional cancer therapies are not an option. Currently, treatment involves surgical removal of the tumours but this leads to damage of the auditory nerve and can cause total deafness with potentially devastating effects on the lives of those involved.

"Great progress has been made in identifying target molecules for treatment, and this research will go a long way towards establishing the best potential drug for non-invasive therapy. Ultimately this would avoid the need for surgery and mean that people who currently face deafness as a result of acoustic neuroma would retain their hearing."


'/>"/>

Contact: Andrew Gould
andrew.gould@pms.ac.uk
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Related medicine news :

1. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
2. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
3. $21.8 Million NIH Grant for Fragile X Research
4. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
5. Boston University School of Medicine researcher recipient of Memory Ride Grant
6. RAND researchers offer options to improve immigrant health care quality, access
7. Pennsylvania Department of Aging Receives Grant to Improve Alzheimers Support
8. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
9. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
10. Johns Hopkins receives $100 million grant to speed research from clinic to community
11. Major grant advances UWs clinical and translational research enterprise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Halfway through its partnership with First 5 LA, Western University of Health ... children 5 years old and younger and treatment services to more than 9,100 of ... years to Western University of Health Sciences, UCLA and USC, beginning March 1, 2013, ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland today ... spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched with ... caregivers the opportunity to share stories and advice, seek help, and continue their education ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... , , ... in 2015, and it is expected to grow at a CAGR of ... to witness faster growth during the forecast period, a CAGR of 8.8% ...
(Date:12/2/2016)... Dec. 2, 2016 In the first ever ... from those derived from C. sativa, the Hebrew University ... di Napoli Federico II , the Universita` del Piemonte ... comprehensive, critical, integrated and unified inventory of phytocannabinoids of ... focuses on the remarkable chemical and structural diversity of ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
Breaking Medicine Technology: